Francis Medical announced today that it has completed an oversubscribed $80 million Series C equity financing.

Background: Androgen ablation is often used in addition to low-dose-rate brachytherapy in the treatment of prostate cancer, particularly for disease with adverse features. We report a single ...

AngioDynamics has obtained an FDA green light for its NanoKnife prostate cancer ablation system ... side effects following radical prostatectomy surgery include about one-third of men showing ...

The system, which was already FDA-cleared for the surgical ablation of soft tissue, is now indicated for prostate tissue ablation ... Conventional radical surgery or radiotherapy often results ...

AngioDynamics, Inc. ANGO, yesterday, announced the receipt of the FDA’s 510(k) clearance for the NanoKnife System for prostate tissue ablation ... conventional radical surgery or radiotherapy ...

The Company received clearance for the NanoKnife System for prostate tissue ablation following the completion ... alternative to conventional radical surgery or radiotherapy, which often results ...

and D90 (percent of the prescribed dose that at least 90% of the prostate received) were averaged for a random sample of 25 patients each in the androgen ablation and no-androgen ablation groups ...